🔗 Visit the ClinicalTrials.gov page for NCT00875979
Rank | Title | Journal | Year | PubWeight™‹?› |
---|---|---|---|---|
1 | Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. | J Clin Oncol | 2014 | 0.91 |
2 | Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. | Breast Cancer (Auckl) | 2014 | 0.87 |
3 | Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer. | Breast Cancer (Auckl) | 2016 | 0.82 |
4 | New clinical advances in immunotherapy for the treatment of solid tumours. | Immunology | 2015 | 0.76 |
5 | Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer. | Onco Targets Ther | 2016 | 0.75 |